From the Literature

Published: Sep 2001

Romero Castro R, Barroso Relinque N, Caunedo Alvarez AC, et al.

Use of recombinant factor VII in hepatology.
Rev Esp Enferm Dig 2001;93(10):664-668.

#

NATA REVIEW:
This article starts with a general overview on mechanism of action, uses and safety of rFVIIa...
REVIEW by:

Published: Sep 2001

Steinitz D, Harvey EJ, Leighton RK, Petrie DP

Is homologous blood transfusion a risk factor for infection after hip replacement?
Can J Surg 2001;44(5):355-358.

#

NATA REVIEW:
Note: It is difficult to ascertain transfusion as a factor entirely separate from co-morbidity. -...
REVIEW by:

Published: Sep 2001

Hudson JQ, Comstock TJ

Considerations for optimal iron use for anemia due to chronic kidney disease.
Clin Ther 2001;23(10):1637-1671.

#

NATA REVIEW:
It is certainly of great value to have an overview about different iron regimens in combination...
REVIEW by:

Published: Sep 2001

Rubin GL, Schofield WN, Dean MG, Shakeshaft AP

Appropriateness of red blood cell transfusions in major urban hospitals and effectiveness of an intervention.
Med J Aust 2001;175(7):354-358.

#

NATA REVIEW:
The article describes a too liberal indication for RBC transfusions if recent knowledge on...
REVIEW by:
Kretschmer V.

Published: Sep 2001

Molenaar IQ, Legnani C, Groenland TH, et al.

Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect.
Liver Transplant 2001;7(10):896-903.

#

NATA REVIEW:
This study supports the hypothesis that aprotinin is an anticoagulant which prolongs the aPTT...
REVIEW by:
W. Dietrich

Published: Sep 2001

Hayes JK, Stanley TH, Lind GH, East K, Smith B, Kessler K

A double-blind study to evaluate the safety of recombinant human hemoglobin in surgical patients during general anesthesia.
J Cardiothorac Vasc Anesth 2001;15(5):593-602.

#

NATA REVIEW:
The authors evaluated the safety profile of escalating doses of rHb1.1 in patients undergoing...
REVIEW by:
Ph. Van der Linden

Published: Sep 2001

Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H

Recombinant activated factor VII (RFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.
Scand J Gastroenterol 2001;36(10):1081-1085.

#

NATA REVIEW:
This is a new open-label study, which showed efficacy of rFVIIa in normalising prothrombin...
REVIEW by:
M. Aldouri

Published: Sep 2001

Farrant B, Battin M, Roberts A

Outcome of infants receiving in-utero transfusions for haemolytic disease.
N Z Med J 2001;114(1139):400-403.

#

NATA REVIEW:
Retrospective analysis of infants receiving in-utero transfusion showing good outcome. No...
REVIEW by:

Published: Aug 2001

Vichinsky EP, Luban NLC, Wright E, et al.

Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.
Transfusion 2001;41(9):1086-1092.

#

NATA REVIEW:
For a transfusionist from West/North Europe, the results are predictable and the conclusion...
REVIEW by:
V. Kretschmer.

Published: Aug 2001

Chuansumrit A, Sri-Udomporn N, Srimuninnimit V, Juntarukha R

A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
Haemophilia 2001;7(5):532-534.

#

NATA REVIEW:
A single dose of rFVIIa (150-180 μg/kg) was used to treat five muscle/joint bleeds and...
REVIEW by:
M. Aldouri

Pages